4P-Pharma cannot select every promising drug candidate they review for co-development. To make prompt, well-informed decisions on which drugs to license, 4P first needs to thoroughly understand the drug and drug development environment for the particular indication. With this information, the company can assess a candidate’s true potential to progress forward through the drug development pipeline. 4P-Pharma needs to quickly determine the suitability of drugs they are considering for licensing, so staff can focus their time and energy on the candidates with the most promise.


4P-Pharma uses the Elsevier R&D Solution PharmaPendium to efficiently review information about a drug molecule’s characteristics and pharmacokinetics and evaluate its upstream potential. This platform is particularly valuable for 4P-Pharma because of the company’s focus on repurposing drugs for new indications. Company staff could search the U.S. Food and Drug Administration and European Medicines Agency websites to acquire this information, but doing so takes days, and pertinent information could get missed.

With PharmaPendium, 4P can extract and organize all the preclinical and clinical data instantaneously. 4P-Pharma Project Manager Luigi Formicola emphasizes that “what is most valuable is the integration of all the data, and the way they are presented. It’s fast, it’s clear. The table is easily searchable … and it saves us a lot of time.”

4P-Pharma also utilizes this platform to determine the key experiments necessary to perform with the drugs they choose to co-develop. The research team uses PharmaPendium almost daily to review previously performed experiments by other drug developers and decide on the parameters of their own experiments.

“It saves us resources. We won’t lose time performing experiments with dosage or route of administration that have been tested before and were shown to be toxic… PharmaPendium provides us with a quality assurance for our results, as we know that we have performed our experiments within the expected standards set [for] approved drugs,” Luigi says. With this ready access to information through PharmaPendium, “we were able to confirm the efficacy and safety of our [stimulant] abuse deterrent” that 4P is bringing forward into early-stage clinical trials.

“With the thoroughness of the drug development plan we conduct,” crafted with the help of PharmaPendium, we have “enforce[d] our credibility as a small biotech with the capability of going forward with preclinical development of a drug candidate.” Luigi also indicated that because of its extensive value, “PharmaPendium is now part of our process for decision-making.”


The time the company would have spent searching for information is time 4P-Pharma staff can spend designing experiments and analyzing results. “We are very happy with PharmaPendium. All the time savings, and the confidence in the data that we got from PharmaPendium, helps us to go faster through our preclinical program. People say ‘you cannot buy time’, however, PharmaPendium is doing exactly that: It is buying us time and that is great for us.”

Nicki Catchpole

Sr. Manager, Pharma and Biotech Segment

As a professional with over 14 years of experience in strategy development and partnership management across a variety of industries, Nicki’s latest role as a Senior Manager, Segment Marketing at Elsevier applies her skills to the area of drug discovery and development in the Pharma and Biotech industry.
In this capacity she is focused on understanding biopharmaceutical R&D challenges and turning them into opportunity to further Elsevier’s ability to serve industry executives and the professionals who innovate in the drug discovery and development space.
Nicki resides in New York City and holds a BA in English Literature and Mandarin Chinese from Carleton College in Northfield, MN.